Related Experiment Video

Updated: Mar 29, 2026

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.2K

Bioinformatic analysis of potential candidates for therapy of inflammatory bowel disease

X L Li1, C Y Zhou, Y Sun

  • 1Pharmacy Department, China-Japan Union Hospital of Jilin University, Changchun, China. changyuzhoucyz@163.com.

European Review for Medical and Pharmacological Sciences
|December 5, 2015
PubMed
Abstract

Insights

Inflammatory bowel diseases (IBDs) increase colorectal cancer risk. This study identifies MAPK3, NDRG1, and HLA-DRA as potential therapeutic targets for IBD treatment.

Area of Science:

  • Gastroenterology and Immunology
  • Molecular Biology
  • Bioinformatics

Background:

  • Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic conditions associated with an increased risk of colorectal cancer.
  • Current therapeutic options for IBDs are limited, highlighting the urgent need for novel treatment strategies.
  • Understanding the molecular mechanisms underlying IBD pathogenesis is crucial for identifying effective therapeutic targets.

Purpose of the Study:

  • To identify potential therapeutic targets for inflammatory bowel disease (IBD).
  • To explore the underlying molecular mechanisms contributing to the development of IBD.
  • To analyze gene expression profiles and protein-protein interaction networks in IBD.

Main Methods:

  • Downloaded gene expression profile GSE6731 from the Gene Expression Omnibus (GEO) database, comprising 9 UC and 19 CD samples.
  • Identified differentially expressed genes (DEGs) between affected and non-affected colon tissues in UC and CD groups.
  • Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, and constructed protein-protein interaction (PPI) networks to identify key genes and modules.

Main Results:

  • Identified 619 DEGs in UC (285 up-regulated, 334 down-regulated) and 1159 DEGs in CD (585 up-regulated, 574 down-regulated).
  • Selected a significant module from the PPI network.
  • Highlighted mitogen-activated protein kinase 3 (MAPK3), N-myc downstream regulated 1 (NDRG1), and major histocompatibility complex, class II, DR alpha (HLA-DRA) as high-degree nodes within the PPI network and module.

Conclusions:

  • MAPK3, NDRG1, and HLA-DRA are implicated as key players in the progression and development of IBD.
  • These identified genes represent potential specific therapeutic targets for IBD treatment.
  • Further experimental validation is required to confirm the role of these genes and their therapeutic potential in IBD.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

590
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.8K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
935
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
618